Takeda Pharmaceutical News

SD: Specialized disclosure report

Apr 25 06:11 ET

6-K: U.S. FDA Approves Subcutaneous Administration of Takeda’s ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn’s Disease

Apr 19 06:15 ET

Takeda Pharmaceutical | 6-K: Notice Regarding Issuance of JPY Hybrid Bonds

Apr 15 06:33 ET

Takeda Pharmaceutical | SC 13D/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Takeda Pharmaceutical Company Limited(4.8%)

Apr 10 06:12 ET

Takeda Pharmaceutical | SC 13D/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Takeda Pharmaceutical Company Limited(5.4%)

Apr 1 06:21 ET

Takeda Pharmaceutical | 6-K: Takeda Announces Candidates for Board of Directors at Upcoming Shareholders Meeting

Mar 27 06:38 ET

Takeda Pharmaceutical | 6-K: Takeda intends to rapidly initiate the first global Phase 3 trials of TAK-861, an oral orexin agonist, in narcolepsy type 1 in first half of fiscal year 2024

Feb 9 06:09 ET

Takeda Pharmaceutical | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-BlackRock, Inc.(7.7%)

Feb 6 09:43 ET

Takeda Pharmaceutical | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Sumitomo Mitsui Trust Holdings, Inc.(5.5%)

Feb 5 06:27 ET

Takeda Pharmaceutical | 6-K: Quarterly Securities Report For The Nine-month Period and Three-month Quarter Ended December 31, 2023

Feb 2 06:20 ET

Takeda Pharmaceutical | 6-K: Takeda Announces Chief Financial Officer Succession

Feb 1 06:21 ET

Takeda Pharmaceutical | 6-K: Summary of Financial Statements for the Nine-month Period Ended December 31, 2023

Feb 1 06:12 ET

Takeda Pharmaceutical | 4: Statement of changes in beneficial ownership of securities-10% Owner TAKEDA PHARMACEUTICAL CO LTD

Jan 25 06:14 ET

Takeda Pharmaceutical | SC 13D/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Takeda Pharmaceutical Company Limited(6.6%)

Jan 25 06:14 ET

Takeda Pharmaceutical | SC 13G: Statement of acquisition of beneficial ownership by individuals-Takeda Pharmaceutical Company Limited(5.2%),Takeda Ventures, Inc(5.2%)

Jan 19 00:00 ET

Takeda Pharmaceutical | 6-K: Announcement of a company split (simplified absorption-type company split/short-form company split) with a wholly-owned subsidiary

Jan 16 00:00 ET

Takeda Pharmaceutical | 6-K: Partial Amendment to Corporate Governance Report

Dec 14, 2023 06:01 ET

Takeda Pharmaceutical | 6-K: The 147th (interim period) Business Report

Nov 30, 2023 06:01 ET

Takeda Pharmaceutical | 6-K: Takeda’s ADZYNMA (ADAMTS13, recombinant-krhn) Approved by U.S. FDA

Nov 13, 2023 06:05 ET

Takeda Pharmaceutical | 6-K: Report of foreign private issuer (related to financial reporting)

Oct 30, 2023 06:02 ET